Bernard FOX

Earle A. Chiles Research Institute, Providence Cancer Institute

Bernard A. Fox, PhD, is the Harder Family Chair for Cancer Research, Member and Chief of the Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute; Founder and CEO of UbiVac, a clinical stage immunotherapy biotech; Adjunct Graduate Faculty, at OHSU and member of the NCI Knight Cancer Institute. Dr. Fox received his B.S. and M.S. from University of Detroit, Ph.D. from Wayne State University and his postgraduate training with Dr. Steven A. Rosenberg, at the NCI, NIH. Since 1994 he has worked to develop the Earle A. Chiles Research Institute into an Internationally recognized center of excellence for cancer Immunotherapy. His research efforts are divided between basic research, moving that research into clinical trials for patients with cancer and training the next generation of investigators. As CEO of UbiVac, and in collaboration with two major pharmaceutical companies, UbiVac’s cancer vaccine technology is in two first-in-human combination immunotherapy trials. Dr. Fox lectures widely, has served on advisory boards for more than 20 pharmaceutical companies and biotechs, and authored more than 170 papers/book chapters. He has served/serves as a Professor at Universities in Germany, Amsterdam, China and Taiwan and as a member of review committees for the NIH, FDA, philanthropic and governmental organizations in the USA, Europe and Asia. Dr. Fox is currently Chair of the World Immunotherapy Council (WIC) and past President of the Society for Immunotherapy of Cancer (SITC). In 2015, Dr. Fox received the Visionary/Legacy Award from SITC and in 2020 a SITC Team Science Award.